Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CV 3317

Known as: CV-3317 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Background: Angiotensin converting enzyme (ACE) inhibitors and Angiotensin II (AII) receptor blockers have previously been shown… Expand
1990
1990
The effect of the newly developed angiotensin-converting enzyme (ACE) inhibitor, delapril hydrochrolide (CV-3317), on the release… Expand
1989
1989
Delapril est administre a dose unique ou a doses repetees et on teste son action antihypertensive et ses effets sur les systemes… Expand
1988
1988
Pharmacokinetic properties of a new angiotensin‐converting enzyme inhibitor, delapril (CV‐3317), which converts to two active… Expand
1986
1986
N-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-N-(indan-2- yl)glycine hydrochloride (CV-3317) and its de-esterified… Expand
1986
1986
The antihypertensive action of N-[N-[(S)-1-ethoxycarbonyl-3-phenyl-propyl]-L-alanyl]-N-(indan-2-yl) glycine hydrochloride (CV… Expand
1986
1986
A new angiotensin converting enzyme (ACE) inhibitor, N-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-N-(indan-2-yl)glycine… Expand